Chronic renal failure secondary prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Chronic renal failure}}
{{Chronic renal failure}}
{{CMG}} {{AE}} {{AN}}
{{CMG}} {{AE}} {{AN}}{{SSW}}
 
== Overview ==
Effective measures for the secondary prevention of chronic renal failure include reducing [[progression]], treating [[Complication (medicine)|complication]], and [[renal replacement therapy]](RRT).


==Secondary Prevention==
==Secondary Prevention==
Line 6: Line 9:
*Protective therapy most effective if initiated '''early''', before [[Creatinine]] > 1.5-2.0 mg/dL  
*Protective therapy most effective if initiated '''early''', before [[Creatinine]] > 1.5-2.0 mg/dL  
**Treat [[Hypertension]]
**Treat [[Hypertension]]
*** Systemic [[hypertension]]--elevated intraglomerular pressure +/or glom hypertrophy
*** Systemic [[hypertension]]--elevated intraglomerular pressure +/or glom hypertrophy.
*** [[Blood Pressure]] (BP) control shown in multiple trials to slow progression of renal disease
*** [[Blood Pressure]] (BP) control shown in multiple trials to slow progression of renal disease.
*** Goal [[Blood pressure]] < 130/80-85; < 125/75 in patients with [[proteinuria]] > 1-2 g/d
*** Goal [[Blood pressure]] < 130/80-85; < 125/75 in patients with [[proteinuria]] > 1-2 g/d.
*** [[ACE inhibitors]] (ACEI) and [[Angiotensin II receptor antagonist|Angiotensin II receptor blockers]] (ARB) preferred 1st line agents due to reno-protective effects
*** [[ACE inhibitors]] (ACEI) and [[Angiotensin II receptor antagonist|Angiotensin II receptor blockers]] (ARB) preferred 1st line agents due to reno-protective effects.<ref name="pmid3651580">{{cite journal |vauthors=Lerche D, Kozlov MM, Markin VS |title=Electrostatic free energy and spontaneous curvature of spherical charged layered membrane |journal=Biorheology |volume=24 |issue=1 |pages=23–34 |date=1987 |pmid=3651580 |doi= |url=}}</ref>
*** Additional agents as needed, including [[diuretics]] if volume overload
*** Additional agents as needed, including [[diuretics]] if volume overload.
** Restrict Dietary Protein
** Restrict Dietary Protein
*** Controversial – may decrease intraglomerular pressure
*** Controversial – may decrease intraglomerular pressure.
*** Conflicting studies – some show benefit, others do not
*** Conflicting studies – some show benefit, others do not.
*** No significant adverse effects shown in large trial
*** No significant adverse effects shown in large trial.
*** Recommendations  
*** Recommendations  
**** No restriction (> 0.8 g/kg/d) if [[GFR]] 25-55 mL/min
**** No restriction (> 0.8 g/kg/d) if [[GFR]] 25-55 mL/min.
**** Limit protein to 0.8 g/kg/d if progression or [[Uremia|uremic]] symptoms
**** Limit protein to 0.8 g/kg/d if progression or [[Uremia|uremic]] symptoms.
**** Limit to 0.6 g/kg/d if severe [[renal insufficiency]] ([[GFR]] 13-25 mL/min)
**** Limit to 0.6 g/kg/d if severe [[renal insufficiency]] ([[GFR]] 13-25 mL/min).
*** Close follow-up by dietician given risk of [[malnutrition]] in this population
*** Close follow-up by dietician given risk of [[malnutrition]] in this population.
** Control [[Blood sugar]]:
** Control [[Blood sugar]]:
*** Tight control ([[HbA1c]] < 7.0, [[Fasting blood sugar 70-120) reduces progression in [[Diabetes Mellitus Type 1|DM I]]
*** Tight control ([[HbA1c]] < 7.0, [[Fasting blood sugar 70-120) reduces progression in [[Diabetes Mellitus Type 1|DM I]].
*** Unclear if as beneficial in [[Diabetes Mellitus Type 2|DM II]], but potentially helpful
*** Unclear if as beneficial in [[Diabetes Mellitus Type 2|DM II]], but potentially helpful.


===Treat complications===
===Treat complications===
* Volume Overload
* Volume Overload
** Impaired excretion of sodium and water due to decreased [[GFR]] +/- [[Aldosterone|AII/aldo]] activation
** Impaired excretion of sodium and water due to decreased [[GFR]] +/- [[Aldosterone|AII/aldo]] activation.
** Restrict dietary sodium to 1-2 g/d if [[hypertension]] or [[edema]]
** Restrict dietary sodium to 1-2 g/d if [[hypertension]] or [[edema]].
** [[Diuretic]]s
** [[Diuretic]]s
*** [[Thiazide]]s ineffective if [[GFR]] < 25 mL/min (~[[Creatinine]] > 2-3)
*** [[Thiazide]]s ineffective if [[GFR]] < 25 mL/min (~[[Creatinine]] > 2-3).
*** Switch to [[Loop diuretic]] as [[Creatinine]] rises; may need bid dosing
*** Switch to [[Loop diuretic]] as [[Creatinine]] rises; may need bid dosing.
*** Addition of [[thiazide]] to [[Loop diuretic]] can--additional [[Diuresis]]
*** Addition of [[thiazide]] to [[Loop diuretic]] can--additional [[Diuresis]].
*** Watch for excessive volume depletion
*** Watch for excessive volume depletion
* [[Hyperkalemia]]
* [[Hyperkalemia]]
** Potassium usually maintained until [[GFR]] < 15-20 mL/min
** Potassium usually maintained until [[GFR]] < 15-20 mL/min.
**Increased risk of [[hyperkalemia]] with [[Oliguria]], high [[K|potassium]] diet, ([[ACEI|ACE inhibitors]] therapy)
**Increased risk of [[hyperkalemia]] with [[Oliguria]], high [[K|potassium]] diet, ([[ACEI|ACE inhibitors]] therapy).
** Increased risk with many meds:  [[ACEI]], [[NSAID]]s, [[Potassium-sparing diuretic]]s, [[digoxin]], [[TMP]]
** Increased risk with many meds:  [[ACEI]], [[NSAID]]s, [[Potassium-sparing diuretic]]s, [[digoxin]], [[TMP]].
** Increased risk in diabetics with [[Renal tubular acidosis|type IV RTA]]
** Increased risk in diabetics with [[Renal tubular acidosis|type IV RTA]]
* Management
* Management
** Low potassium diet (< 60 mEq/d) once GFR < 15 mL/min
** Low potassium diet (< 60 mEq/d) once GFR < 15 mL/min.
** Avoidance of salt substitutes (may contain potassium salts)
** Avoidance of salt substitutes (may contain potassium salts).
** +/- [[loop diuretic]]
** +/- [[loop diuretic]]
** Low dose [[Kayexelate]] (5 g with meals) if needed  
** Low dose [[Kayexelate]] (5 g with meals) if needed.
* Calcium/phosphate Abnormalities
* Calcium/phosphate Abnormalities
** Reduced renal synthesis [[Calcitriol]]/[[Vitamin D]]--low serum Calcium-- [[Secondary hyperparathyroidism]]
** Reduced renal synthesis [[Calcitriol]]/[[Vitamin D]]--low serum Calcium-- [[Secondary hyperparathyroidism]].
** (Occurs when [[GFR]] < 40 mL/min)
** (Occurs when [[GFR]] < 40 mL/min)
** Reduced [[GFR]]--phosphate retention  
** Reduced [[GFR]]--phosphate retention  
** Elevated [[parathyroid hormone]] ([[PTH]])--mobilization of Calcium from bone; increased excretion phosphate
** Elevated [[parathyroid hormone]] ([[PTH]])--mobilization of Calcium from bone; increased excretion phosphate.
** Allows maintenance of normal Calcium/phosphate while [[GFR]] > 30 mL/min
** Allows maintenance of normal Calcium/phosphate while [[GFR]] > 30 mL/min.
** Causes [[renal osteodystrophy]]
** Causes [[renal osteodystrophy]]
** Once [[GFR]] < 25-30 mL/min, [[hyperphosphatemia]] occurs
** Once [[GFR]] < 25-30 mL/min, [[hyperphosphatemia]] occurs
** Therapy goals = normalize Calcium/Phosphate and maintain [[parathyroid hormone]] (PTH)< 200 (2-3x uln)
** Therapy goals = normalize Calcium/Phosphate and maintain [[parathyroid hormone]] (PTH)< 200 (2-3x uln).
*** Calcium/Phosphate management should be initiated when [[Creatinine]] ~ 2  
*** Calcium/Phosphate management should be initiated when [[Creatinine]] ~ 2.
*** Calcium x phosphate product should be < 60 to prevent met calcification
*** Calcium x phosphate product should be < 60 to prevent met calcification.
*** Low phosphate diet:  < 800 mg/d (challenging)
*** Low phosphate diet:  < 800 mg/d (challenging)
*** Calcium-based oral phosphate binders:  Calcium acetate or Calcium carbonate with meals
*** Calcium-based oral phosphate binders:  Calcium acetate or Calcium carbonate with meals.
*** Avoid Aluminium-based phosphate binders except for acute therapy of high Calcium x Phosphate products
*** Avoid Aluminium-based phosphate binders except for acute therapy of high Calcium x Phosphate products.
**** (Aluminium toxicity = [[osteomalacia]], [[anemia]], [[encephalopathy]])
**** (Aluminium toxicity = [[osteomalacia]], [[anemia]], [[encephalopathy]])
*** Avoid Calcium citrate (increases gastrointestinal absorption of aluminum)
*** Avoid Calcium citrate (increases gastrointestinal absorption of aluminum)
**** RenaGel = new non-Calcium/Aluminium-containing phosphate binder (cationic polymer)  
**** RenaGel = new non-Calcium/Aluminium-containing phosphate binder (cationic polymer).
***** (For patients who cannot tolerate Calcium carbonate or need additional agent)
***** (For patients who cannot tolerate Calcium carbonate or need additional agent)
**** [[Calcitriol]] 0.125-0.25 mg/d improves Calcium & [[Parathyroid hormone]] levels, decreases bone disease
**** [[Calcitriol]] 0.125-0.25 mg/d improves Calcium & [[Parathyroid hormone]] levels, decreases bone disease.
***** (Monitor Calcium--reduce dose if [[Hypercalcemia|hypercalcemic]])
***** (Monitor Calcium--reduce dose if [[Hypercalcemia|hypercalcemic]])
*[[Metabolic Acidosis]]
*[[Metabolic Acidosis]]
**Occurs when [[GFR]] < 25 mL/min due to inability to excrete H+ ions
**Occurs when [[GFR]] < 25 mL/min due to inability to excrete H+ ions.
**Underlying cause = impaired renal ammonia production and bicarbonate reabsorption
**Underlying cause = impaired renal ammonia production and bicarbonate reabsorption.
**Risk = bone buffering of [[acidosis]]--worsened [[Osteodystrophy]] via Calcium/phosphate loss
**Risk = bone buffering of [[acidosis]]--worsened [[Osteodystrophy]] via Calcium/phosphate loss.
**Increased skeletal muscle breakdown--loss of lean body mass
**Increased skeletal muscle breakdown--loss of lean body mass.
**Therapy goal = bicarbonate > 22 mEq/L via alkali therapy (NaHCO3 0.5-1 mEq/kg/d)
**Therapy goal = bicarbonate > 22 mEq/L via alkali therapy (NaHCO3 0.5-1 mEq/kg/d)
*[[Anemia]]
*[[Anemia]]
**[[Normocytic normochromic anemia]] due to reduced [[Erythropoietin]] production
**[[Normocytic normochromic anemia]] due to reduced [[Erythropoietin]] production.
**May be exacerbated by reduced [[RBC]] survival, coexistent iron/folate deficiency, etc.
**May be exacerbated by reduced [[RBC]] survival, coexistent iron/folate deficiency, etc.
**Generally occurs when [[Creatinine]] > 2-3 mg/dL
**Generally occurs when [[Creatinine]] > 2-3 mg/dL.
**If untreated, [[hematocrit]] (Hct) usually stabilizes at ~ 25
**If untreated, [[hematocrit]] (Hct) usually stabilizes at ~ 25.
**Therapy recommendations = [[Erythropoietin]] if symptomatic [[anemia]] or [[Hemoglobin]] < 10 g/dL (in pre-dialysis patients)
**Therapy recommendations = [[Erythropoietin]] if symptomatic [[anemia]] or [[Hemoglobin]] < 10 g/dL (in pre-dialysis patients).
**Goal [[Hematocrit]] 33-36
**Goal [[Hematocrit]] 33-36
**Must replete iron stores first (oral ferrous sulfate)
**Must replete iron stores first (oral ferrous sulfate)
**Initial dose ~ 150 U/kg sc weekly to increase [[Hematocrit]]
**Initial dose ~ 150 U/kg sc weekly to increase [[Hematocrit]].
**Maintenance dose ~ 75 U/kg weekly once [[Hematocrit]] goal reached
**Maintenance dose ~ 75 U/kg weekly once [[Hematocrit]] goal reached.
**Improves symtoms and may reduce left ventricle (LV) mass (via improvemt of hyperdynamic state)
**Improves symtoms and may reduce left ventricle (LV) mass (via improvemt of hyperdynamic state).
**Side effects = increased [[blood pressure]] (BP); may need to augment [[Antihypertensive]] regimen
**Side effects = increased [[blood pressure]] (BP); may need to augment [[Antihypertensive]] regimen.
===Plan for Renal Replacement Therapy (RRT)===
===Plan for Renal Replacement Therapy (RRT)===
*Indications for [[Dialysis]]
*Indications for [[Dialysis]]
Line 99: Line 102:
**[[Peritoneal dialysis]]
**[[Peritoneal dialysis]]
**[[Renal transplant]]
**[[Renal transplant]]
*Access for [[hemodialysis]] should be established when [[GFR]] < 25 mL/min (estimated [[Chronic renal failure]] within 1 year)
*Access for [[hemodialysis]] should be established when [[GFR]] < 25 mL/min (estimated [[Chronic renal failure]] within 1 year).
*Diabetics tend to require [[dialysis]] sooner than non-diabetics because more symptomatic at given [[GFR]]
*Diabetics tend to require [[dialysis]] sooner than non-diabetics because more symptomatic at given [[GFR]].
*Indications for referral to nephrologist
*Indications for referral to nephrologist
**Unclear etiology of new or chronic [[renal insufficiency]]  
**Unclear etiology of new or chronic [[renal insufficiency]]  

Latest revision as of 19:11, 6 August 2018

Chronic renal failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic renal failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic renal failure secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic renal failure secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic renal failure secondary prevention

CDC on Chronic renal failure secondary prevention

Chronic renal failure secondary prevention in the news

Blogs on Chronic renal failure secondary prevention

Directions to Hospitals Treating Chronic renal failure

Risk calculators and risk factors for Chronic renal failure secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]Sargun Singh Walia M.B.B.S.[3]

Overview

Effective measures for the secondary prevention of chronic renal failure include reducing progression, treating complication, and renal replacement therapy(RRT).

Secondary Prevention

Reduce Progression

  • Protective therapy most effective if initiated early, before Creatinine > 1.5-2.0 mg/dL
    • Treat Hypertension
    • Restrict Dietary Protein
      • Controversial – may decrease intraglomerular pressure.
      • Conflicting studies – some show benefit, others do not.
      • No significant adverse effects shown in large trial.
      • Recommendations
        • No restriction (> 0.8 g/kg/d) if GFR 25-55 mL/min.
        • Limit protein to 0.8 g/kg/d if progression or uremic symptoms.
        • Limit to 0.6 g/kg/d if severe renal insufficiency (GFR 13-25 mL/min).
      • Close follow-up by dietician given risk of malnutrition in this population.
    • Control Blood sugar:
      • Tight control (HbA1c < 7.0, [[Fasting blood sugar 70-120) reduces progression in DM I.
      • Unclear if as beneficial in DM II, but potentially helpful.

Treat complications

  • Volume Overload
  • Hyperkalemia
  • Management
    • Low potassium diet (< 60 mEq/d) once GFR < 15 mL/min.
    • Avoidance of salt substitutes (may contain potassium salts).
    • +/- loop diuretic
    • Low dose Kayexelate (5 g with meals) if needed.
  • Calcium/phosphate Abnormalities
    • Reduced renal synthesis Calcitriol/Vitamin D--low serum Calcium-- Secondary hyperparathyroidism.
    • (Occurs when GFR < 40 mL/min)
    • Reduced GFR--phosphate retention
    • Elevated parathyroid hormone (PTH)--mobilization of Calcium from bone; increased excretion phosphate.
    • Allows maintenance of normal Calcium/phosphate while GFR > 30 mL/min.
    • Causes renal osteodystrophy
    • Once GFR < 25-30 mL/min, hyperphosphatemia occurs
    • Therapy goals = normalize Calcium/Phosphate and maintain parathyroid hormone (PTH)< 200 (2-3x uln).
      • Calcium/Phosphate management should be initiated when Creatinine ~ 2.
      • Calcium x phosphate product should be < 60 to prevent met calcification.
      • Low phosphate diet: < 800 mg/d (challenging)
      • Calcium-based oral phosphate binders: Calcium acetate or Calcium carbonate with meals.
      • Avoid Aluminium-based phosphate binders except for acute therapy of high Calcium x Phosphate products.
      • Avoid Calcium citrate (increases gastrointestinal absorption of aluminum)
        • RenaGel = new non-Calcium/Aluminium-containing phosphate binder (cationic polymer).
          • (For patients who cannot tolerate Calcium carbonate or need additional agent)
        • Calcitriol 0.125-0.25 mg/d improves Calcium & Parathyroid hormone levels, decreases bone disease.
  • Metabolic Acidosis
    • Occurs when GFR < 25 mL/min due to inability to excrete H+ ions.
    • Underlying cause = impaired renal ammonia production and bicarbonate reabsorption.
    • Risk = bone buffering of acidosis--worsened Osteodystrophy via Calcium/phosphate loss.
    • Increased skeletal muscle breakdown--loss of lean body mass.
    • Therapy goal = bicarbonate > 22 mEq/L via alkali therapy (NaHCO3 0.5-1 mEq/kg/d)
  • Anemia

Plan for Renal Replacement Therapy (RRT)

Recent studies have shown no benefits of initiating early dialysis with improved patient survival. [2]However, advanced preparation for dialysis can help avoid complications like poorly functioning fistula for hemodialysis or malfunctioning peritoneal dialysis catheter, sepsis, bleeding and thrombosis.


References

  1. ↑ Lerche D, Kozlov MM, Markin VS (1987). "Electrostatic free energy and spontaneous curvature of spherical charged layered membrane". Biorheology. 24 (1): 23–34. PMID 3651580.
  2. ↑ Cooper BA, Branley P, Bulfone L; et al. (2010). "A randomized, controlled trial of early versus late initiation of dialysis". The New England Journal of Medicine. 363 (7): 609–19. doi:10.1056/NEJMoa1000552. PMID 20581422. Unknown parameter |month= ignored (help)


Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Chronic_renal_failure_secondary_prevention&oldid=1488752"